Adverse Events
migraine, CWP, asthma, COVID-19 gastroenteritis
ADVERSE EVENTS, MIGRAINE, ASTHMA, COVID-19 PNEUMONITIS
No unexpected serious adverse events or intervention-related adverse events occurred during the trial. Overall, five participants were hospitalized during the 16-week period: three participants in the UC group (one participant with a ward level exacerbation of asthma, one participant with exacerbation of asthma requiring high dependency monitoring, one participant with COVID-19 pneumonitis) and two participants in the CWP group (one participant with COVID-19 gastroenteritis and one participant with migraine).